Hepatitis Monthly

Published by: Kowsar

NAFLD Prevalence in a Young Cadaveric Organ Donor Population

Ali Jafarian 1 , * , Amirpasha Ebrahimi 1 , Farid Azmoudeh Ardalan 2 , Habibollah Dashti 1 , Mojgan Rahimi 3 , Mandana Salehi 1 and Mohsen Nasiri Toosi 4
Authors Information
1 Hepatobiliary and Liver Transplantation Division, Department of General Surgery, Imam-Khomeini Hospital, Tehran University of Medical Sciences (TUMS), Tehran, IR Iran
2 Department of Pathology, Imam-Khomeini Hospital, Tehran University of Medical Sciences (TUMS), Tehran, IR Iran
3 Department of Anesthesiology and Intensive Care, Imam-Khomeini Hospital, Tehran University of Medical Sciences (TUMS), Tehran, IR Iran
4 Gastroenterology Division, Internal Medicine Department, Imam-Khomeini Hospital, Tehran University of Medical Sciences (TUMS), Tehran, IR Iran
Article information
  • Hepatitis Monthly: October 2014, 14 (10); e21574
  • Published Online: October 1, 2014
  • Article Type: Research Article
  • Received: June 28, 2014
  • Revised: September 4, 2014
  • Accepted: September 11, 2014
  • DOI: 10.5812/hepatmon.21574

To Cite: Jafarian A, Ebrahimi A, Azmoudeh Ardalan F, Dashti H, Rahimi M, et al. NAFLD Prevalence in a Young Cadaveric Organ Donor Population, Hepat Mon. 2014 ;14(10):e21574. doi: 10.5812/hepatmon.21574.

Copyright: Copyright © 2014, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Farrell GC, George J, Hall PDLM, McCullough AJ. Fatty liver disease. 2008;
  • 2. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003; 37(6): 1286-92[DOI][PubMed]
  • 3. Hui JM, Farrell GC, Kench JG, George J. High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. Hepatology. 2004; 39(5): 1458-9[DOI][PubMed]
  • 4. Loria P, Lonardo A, Leonardi F, Fontana C, Carulli L, Verrone AM, et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci. 2003; 48(11): 2173-81[PubMed]
  • 5. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology. 2004; 39(4): 909-14[DOI][PubMed]
  • 6. Luef GJ, Waldmann M, Sturm W, Naser A, Trinka E, Unterberger I, et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol. 2004; 55(5): 729-32[DOI][PubMed]
  • 7. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol. 2001; 35(4): 531-7[PubMed]
  • 8. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut. 1997; 41(6): 845-50[PubMed]
  • 9. Hayashi PH, Harrison SA, Torgerson S, Perez TA, Nochajski T, Russell M. Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol related. Am J Gastroenterol. 2004; 99(1): 76-81[PubMed]
  • 10. Clarkson VC, Hall P,, Shephard E, Kirsch R, Marais D. Ethanol feeding increases CYP2E11 activity in the methionine choline deficient mouse model for NASH (Abstract). Liver Int J. 2004; 24: 18
  • 11. Laurin J. Motion - all patients with NASH need to have a liver biopsy: arguments against the motion. Can J Gastroenterol. 2002; 16(10): 722-6[PubMed]
  • 12. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003; 112(1): 91-100[DOI][PubMed]
  • 13. Nanji AA. Another animal model for nonalcoholic steatohepatitis: how close to the human condition? Am J Clin Nutr. 2004; 79(3): 350-1[PubMed]
  • 14. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, et al. Model of nonalcoholic steatohepatitis. Am J Clin Nutr. 2004; 79(3): 502-9[PubMed]
  • 15. Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Stravitz RT, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol. 2003; 98(9): 2064-71[DOI][PubMed]
  • 16. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004; 126(2): 586-97[PubMed]
  • 17. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. 2003; 125(6): 1695-704[PubMed]
  • 18. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004; 40(1): 46-54[DOI][PubMed]
  • 19. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004; 350(23): 2362-74[DOI][PubMed]
  • 20. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000; 124(11): 1599-607[DOI][PubMed]
  • 21. Starkel P, Sempoux C, Leclercq I, Herin M, Deby C, Desager JP, et al. Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol. 2003; 39(4): 538-46[PubMed]
  • 22. Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004; 39(1): 179-87[DOI][PubMed]
  • 23. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology. 2002; 122(2): 352-65[PubMed]
  • 24. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 2000; 33(1): 106-15[PubMed]
  • 25. Castera L, Hezode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut. 2003; 52(2): 288-92[PubMed]
  • 26. Nitecki J, Jackson FW, Allen ML, Farr VL, Jackson FW. Effect of phlebotomy on non-alcoholic steatohepatitis. Gastroenterology . 2000; 118
  • 27. Alavian SM, Mohammad-Alizadeh AH, Esna-Ashari F, Ardalan G, Hajarizadeh B. Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures. Liver Int. 2009; 29(2): 159-63[DOI][PubMed]
  • 28. Rogha M, Najafi N, Azari A, Kaji M, Pourmoghaddas Z, Rajabi F, et al. Non-alcoholic Steatohepatitis in a Sample of Iranian Adult Population: Age is a Risk Factor. Int J Prev Med. 2011; 2(1): 24-7[PubMed]
  • 29. Sohrabpour A, Rezvan H, Amini-Kafiabad S, Dayhim M, Merat S, Pourshams A. Prevalence of Nonalcoholic Steatohepatitis in Iran: A Population based Study. Middle East J Dig Dis. 2010; 2(1): 14-9[PubMed]
  • 30. Merat S, Yarahmadi S, Tahaghoghi S, Alizadeh Z. Prevalence of Fatty Liver Disease among Type 2 Diabetes Mellitus Patients and its Relation to Insulin Resistance. Middle East J Dig Dis. 2011; 1(2): 74-9
  • 31. Hubscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology. 2006; 49(5): 450-65[DOI][PubMed]
  • 32. Vigano M, Vergani A, Trombini P, Paleari F, Piperno A. Insulin resistance influence iron metabolism and hepatic steatosis in type II diabetes. Gastroenterology. 2000; 118(5): 986-7[PubMed]
  • 33. Lankarani KB, Ghaffarpasand F, Mahmoodi M, Lotfi M, Zamiri N, Heydari ST, et al. Non alcoholic fatty liver disease in southern Iran: a population based study. Hepat Mon. 2013; 13(5)[DOI][PubMed]
  • 34. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6): 1313-21[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader